A recent meta-analysis demonstrated that SGLT-2 inhibitors significantly improve endothelial function as measured by FMD [PMD: 0.95% (95% CI 0.18–1.73)], and DPP-4 inhibitors [PMD: −0.18 m/s (95% CI −0.3 to −0.07)], SGLT-2 inhibitors [PMD: −1.30 m/s (95% CI −2.41 to −0.19)] and GLP-1 receptor agonists [PMD: −1.97 m/s (95% CI −2.65 to −1.30)] significantly decrease arterial stiffness in type 2 diabetic patients as measured by PWV (242, 278). This evidence concerns the gene DPP4 and type 2 diabetes mellitus.